Literature DB >> 16574311

RS5444, a novel PPARgamma agonist, regulates aspects of the differentiated phenotype in nontransformed intestinal epithelial cells.

Lu Chen1, Craig R Bush, Brian M Necela, Weidong Su, Masahiro Yanagisawa, Panos Z Anastasiadis, Alan P Fields, E Aubrey Thompson.   

Abstract

Peroxisome proliferator-activated receptor-gamma (PPARgamma) is expressed in the intestinal epithelium, yet little is known about the physiological role of PPARgamma in the small bowel or the effects of PPARgamma on small intestinal epithelial cells. The present studies investigate cellular and genomic effects of PPARgamma in nontransformed rat intestinal epithelial cells (RIE). These cells were engineered to express mouse PPARgamma1, and thereby to model the molecular phenotype that obtains upon induction of PPARgamma at the crypt/villus junction in the small intestine. In these studies, we have used a novel third generation thiazolidinedione derivative, RS5444, which activates PPARgamma with an EC50 about 1/50th that of rosiglitazone and has no effect on RIE cells that do not express PPARgamma. We used Affymetrix oligonucleotide microarrays to identify potential PPARgamma-regulated processes in RIE cells, including lipid metabolism, cell proliferation and differentiation, remodeling of the extracellular matrix, cell morphology, cell-cell adhesion, and motility. The genomic profile reflects cellular events that occur following PPARgamma activation: RS5444 inhibited culture growth and caused irreversible G1 arrest, but did not induce apoptosis. In addition, RS5444 caused dramatic changes in cellular morphology which were associated with increased motility and diminished cellular adherence, but no increase in the ability of such cells to digest and invade Matrigel. Inhibition of proliferation, cell cycle arrest, increased motility, and altered adherence are aspects of the differentiated phenotype of villus epithelial cells, which withdraw from the cell cycle at the crypt/villus interface, migrate to the villus tips, and are subsequently shed by loss of contact with the epithelium and the underlying extracellular matrix. Our results are consistent with the hypothesis that PPARgamma regulates critical aspects of differentiation in the small intestinal epithelium. Many nuclear receptors regulate differentiation. However, our results point to novel effects of PPARgamma on cell-cell and cell-matrix interactions, which are not typical of other nuclear receptors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16574311     DOI: 10.1016/j.mce.2006.02.006

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  15 in total

Review 1.  Ontogeny, growth and development of the small intestine: Understanding pediatric gastroenterology.

Authors:  Laurie A Drozdowski; Tom Clandinin; Alan B R Thomson
Journal:  World J Gastroenterol       Date:  2010-02-21       Impact factor: 5.742

Review 2.  Peroxisome proliferator-activated receptors and cancer: challenges and opportunities.

Authors:  Jihan Youssef; Mostafa Badr
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

3.  Transcriptional Regulation of Human Cytosolic Sulfotransferase 1C3 by Peroxisome Proliferator-Activated Receptor γ in LS180 Human Colorectal Adenocarcinoma Cells.

Authors:  Sarah Dubaisi; Hailin Fang; Thomas A Kocarek; Melissa Runge-Morris
Journal:  Mol Pharmacol       Date:  2016-08-26       Impact factor: 4.436

4.  Immunoregulatory actions of epithelial cell PPAR gamma at the colonic mucosa of mice with experimental inflammatory bowel disease.

Authors:  Saroj K Mohapatra; Amir J Guri; Montse Climent; Cristina Vives; Adria Carbo; William T Horne; Raquel Hontecillas; Josep Bassaganya-Riera
Journal:  PLoS One       Date:  2010-04-20       Impact factor: 3.240

5.  Peroxisome proliferator-activated receptor gamma down-regulates follistatin in intestinal epithelial cells through SP1.

Authors:  Brian M Necela; Weidong Su; E Aubrey Thompson
Journal:  J Biol Chem       Date:  2008-09-03       Impact factor: 5.157

6.  Toll-like receptor 4 mediates cross-talk between peroxisome proliferator-activated receptor gamma and nuclear factor-kappaB in macrophages.

Authors:  Brian M Necela; Weidong Su; E Aubrey Thompson
Journal:  Immunology       Date:  2008-04-18       Impact factor: 7.397

7.  The high affinity peroxisome proliferator-activated receptor-gamma agonist RS5444 inhibits both initiation and progression of colon tumors in azoxymethane-treated mice.

Authors:  Weidong Su; Brian M Necela; Kosaku Fujiwara; Shinichi Kurakata; Nicole R Murray; Alan P Fields; E Aubrey Thompson
Journal:  Int J Cancer       Date:  2008-09-01       Impact factor: 7.396

8.  Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth.

Authors:  Laura A Marlow; Lisa A Reynolds; Alan S Cleland; Simon J Cooper; Michelle L Gumz; Shinichi Kurakata; Kosaku Fujiwara; Ying Zhang; Thomas Sebo; Clive Grant; Bryan McIver; J Trad Wadsworth; Derek C Radisky; Robert C Smallridge; John A Copland
Journal:  Cancer Res       Date:  2009-02-10       Impact factor: 12.701

9.  The PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.

Authors:  Rebecca E Nakles; Bhaskar V S Kallakury; Priscilla A Furth
Journal:  Am J Pathol       Date:  2013-05-08       Impact factor: 4.307

10.  Current understanding of the role of PPARγ in gastrointestinal cancers.

Authors:  Bing Zou; Liang Qiao; Benjamin C Y Wong
Journal:  PPAR Res       Date:  2009-10-26       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.